EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Efficacy and Safety of JAK Inhibitors in Lichen Planus: A Systematic Review of the Available Clinical Evidence

Wiktoria Bajek iD, Anna Gwóźdź iD, Aleksandra Kozik iD, Aleksandra Spyra iD, Wiktor Kruczek iD, Aleksandra Frątczak iD, Anna Tekielak iD, Beata Bergler-Czop iD, Bartosz Miziołek iD

Mediators of Inflammation · 2026

DOI: 10.1155/mi/1711381 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Mediators of Inflammation, 2026. Verfasst von Wiktoria Bajek und 8 weiteren Autor:innen. Beteiligte Einrichtung: Students Scientific Association, Department of Dermatology, Medical University of Silesia, Katowice, Poland, sum.edu.pl. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Lichen Planus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Śląski Uniwersytet Medyczny.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lichen planus (LP) is a chronic, immune‐mediated inflammatory disorder affecting the skin, mucous membranes, hair, and nails. Conventional therapies such as corticosteroids and systemic immunosuppressants often demonstrate limited efficacy and are associated with undesirable side effects. The underlying inflammatory process is largely dominated by Th1/IFN‐ɣ cytokines and the activation of the Janus kinase (JAK)‐STAT pathway, highlighting JAK inhibitors as a novel, targeted therapeutic approach for recalcitrant forms of LP.

Aim

The aim of the study was to systematically analyze the current scientific evidence regarding the efficacy and safety of JAK inhibitors in the treatment of various LP variants. Material and Methods A comprehensive literature search was performed in accordance with PRISMA guidelines using PubMed, Scopus, and Cochrane databases from inception up to May 2026. Eighty‐four relevant studies were enrolled into the final analysis. The risk of bias and quality of evidence were assessed using the JBI critical appraisal tools.

Results

The final analysis consisted predominantly of case reports, case series, and limited controlled trials. Both systemic agents (e.g., tofacitinib, upadacitinib, and baricitinib) and topical formulations (e.g., ruxolitinib) demonstrated rapid reductions in pruritus and pain, followed by clinical resolution of inflammatory lesions. High rates of complete and partial clinical responses were observed across diverse variants. Short‐term adverse effects were generally mild and manageable, although the overall certainty of the evidence was low.

Conclusions

JAK inhibitors demonstrate a promising preliminary clinical response and acceptable short‐term safety for managing refractory LP variants. While these agents present a valuable alternative to conventional therapies, the current evidence relies heavily on observational data. Large, randomized controlled trials with long‐term follow‐up are needed to establish optimal dosing, confirm safety, and evaluate sustained efficacy in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase InhibitorsLichen PlanusHumansAzetidinesPurinesPyrimidinesPyrazolesSulfonamidesPiperidinesHeterocyclic Compounds, 3-RingNitrilesPyrroles

Stichwörter der Autor:innen

JAK inhibitorJanus kinase inhibitorlichen planus

Substanzen

Janus Kinase InhibitorstofacitinibAzetidinesPurinesPyrimidinesPyrazolesbaricitinibSulfonamidesPiperidinesupadacitinib

Autor:innen und Institutionen

  • Students Scientific Association, Department of Dermatology, Medical University of Silesia, Katowice, Poland, sum.edu.pl.
  • Doctoral School, Medical University of Silesia, Katowice, Poland, sum.edu.pl.
  • Chair and Department of Dermatology, Medical University of Silesia, Katowice, Poland, sum.edu.pl.

ORCID-Profile: Wiktoria Bajek, Anna Gwóźdź, Aleksandra Kozik, Aleksandra Spyra, Wiktor Kruczek, Aleksandra Frątczak, Anna Tekielak, Beata Bergler-Czop, Bartosz Miziołek

Förderung

  • Śląski Uniwersytet Medyczny

Zitieren

APA

Bajek, W., Gwóźdź, A., Kozik, A., Spyra, A., Kruczek, W., Frątczak, A., Tekielak, A., Bergler-Czop, B., & Miziołek, B. (2026). Efficacy and Safety of JAK Inhibitors in Lichen Planus: A Systematic Review of the Available Clinical Evidence. Mediators of Inflammation. https://doi.org/10.1155/mi/1711381

Vancouver

Bajek W, Gwóźdź A, Kozik A, Spyra A, Kruczek W, Frątczak A, et al. Efficacy and Safety of JAK Inhibitors in Lichen Planus: A Systematic Review of the Available Clinical Evidence. Mediators of Inflammation. 2026. doi:10.1155/mi/1711381

BibTeX
@article{Bajek2026,
  author = {Bajek, Wiktoria and Gwóźdź, Anna and Kozik, Aleksandra and Spyra, Aleksandra and Kruczek, Wiktor and Frątczak, Aleksandra and Tekielak, Anna and Bergler-Czop, Beata and Miziołek, Bartosz},
  title = {Efficacy and Safety of JAK Inhibitors in Lichen Planus: A Systematic Review of the Available Clinical Evidence},
  journal = {Mediators of Inflammation},
  year = {2026},
  doi = {10.1155/mi/1711381}
}
Kostenlos starten →